EP3273975A4 - Noeud lymphatique artificiel in vitro de sensibilisation et de multiplication de lymphocytes t pour la thérapie et la cartographie des épitopes - Google Patents

Noeud lymphatique artificiel in vitro de sensibilisation et de multiplication de lymphocytes t pour la thérapie et la cartographie des épitopes Download PDF

Info

Publication number
EP3273975A4
EP3273975A4 EP16769745.7A EP16769745A EP3273975A4 EP 3273975 A4 EP3273975 A4 EP 3273975A4 EP 16769745 A EP16769745 A EP 16769745A EP 3273975 A4 EP3273975 A4 EP 3273975A4
Authority
EP
European Patent Office
Prior art keywords
sensitization
therapy
expansion
cells
lymph node
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16769745.7A
Other languages
German (de)
English (en)
Other versions
EP3273975A1 (fr
Inventor
Lea LOWENFELD
Brian J. Czerniecki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of EP3273975A1 publication Critical patent/EP3273975A1/fr
Publication of EP3273975A4 publication Critical patent/EP3273975A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16769745.7A 2015-03-26 2016-03-25 Noeud lymphatique artificiel in vitro de sensibilisation et de multiplication de lymphocytes t pour la thérapie et la cartographie des épitopes Withdrawn EP3273975A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562138969P 2015-03-26 2015-03-26
US201562138684P 2015-03-26 2015-03-26
PCT/US2016/024146 WO2016154508A1 (fr) 2015-03-26 2016-03-25 Noeud lymphatique artificiel in vitro de sensibilisation et de multiplication de lymphocytes t pour la thérapie et la cartographie des épitopes

Publications (2)

Publication Number Publication Date
EP3273975A1 EP3273975A1 (fr) 2018-01-31
EP3273975A4 true EP3273975A4 (fr) 2018-10-17

Family

ID=56977770

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16769745.7A Withdrawn EP3273975A4 (fr) 2015-03-26 2016-03-25 Noeud lymphatique artificiel in vitro de sensibilisation et de multiplication de lymphocytes t pour la thérapie et la cartographie des épitopes

Country Status (5)

Country Link
EP (1) EP3273975A4 (fr)
JP (1) JP2018510644A (fr)
CN (1) CN108289910A (fr)
CA (1) CA2981033A1 (fr)
WO (1) WO2016154508A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986687A1 (fr) * 2015-05-22 2016-12-01 Brian J. Czerniecki Fabrication de vaccins multidoses prets a injecter a base de cellules dendritiques
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CA3074826A1 (fr) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Compositions proteiques therapeutiques et procedes de preparation et d'utilisation de celles-ci
WO2019196087A1 (fr) * 2018-04-13 2019-10-17 Syz Cell Therapy Co. Méthodes de traitement du cancer faisant appel à des lymphocytes t spécifiques à un antigène tumoral

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182870A1 (en) * 2009-08-24 2011-07-28 Leen Ann M Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
WO2012140127A2 (fr) * 2011-04-13 2012-10-18 Immunicum Ab Procédé d'amorçage de cellules t

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100035282A1 (en) * 2005-08-03 2010-02-11 Maria Chiara Bonini Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes
WO2010027094A1 (fr) * 2008-09-08 2010-03-11 独立行政法人理化学研究所 CELLULES iPS ISSUES DE CELLULES NKT ET CELLULES NKT ASSOCIEES
WO2011146473A1 (fr) * 2010-05-17 2011-11-24 Duke University Procédés de traitement à l'aide de l'expansion in vivo de lymphocytes t du sang du cordon ombilical
EP2618835B1 (fr) * 2010-09-20 2017-07-05 BioNTech Cell & Gene Therapies GmbH Récepteur des cellules t spécifiques des antigènes et épitopes des cellules t
US8741642B2 (en) * 2010-10-22 2014-06-03 Virginia Commonwealth University Methods for producing autologous immune cells resistant to myeloid-derived suppressor cells effects

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182870A1 (en) * 2009-08-24 2011-07-28 Leen Ann M Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
WO2012140127A2 (fr) * 2011-04-13 2012-10-18 Immunicum Ab Procédé d'amorçage de cellules t

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016154508A1 *
SONIA A PEREZ ET AL: "HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4+ T cell clones", CANCER IMMUNOLOGY, IMMUNOTHE, SPRINGER, BERLIN/HEIDELBERG, vol. 50, no. 11, 1 January 2002 (2002-01-01), pages 615 - 624, XP009138053, ISSN: 0340-7004, [retrieved on 20011123], DOI: 10.1007/S002620100225 *
SOTIRIADOU R ET AL: "Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 85, no. 10, 16 November 2001 (2001-11-16), pages 1527 - 1534, XP002293865, ISSN: 0007-0920, DOI: 10.1054/BJOC.2001.2089 *

Also Published As

Publication number Publication date
EP3273975A1 (fr) 2018-01-31
CA2981033A1 (fr) 2016-09-29
WO2016154508A1 (fr) 2016-09-29
JP2018510644A (ja) 2018-04-19
WO2016154508A8 (fr) 2018-03-15
CN108289910A (zh) 2018-07-17

Similar Documents

Publication Publication Date Title
IL275433A (en) Artificial antigen-presenting cells and methods of use
EP3273987A4 (fr) Méthode utilisant un ganglion lymphatique artificiel in vitro pour la sensibilisation et l'expansion de lymphocytes t dans la thérapie et la cartographie des épitopes
EP3328399A4 (fr) Cellules modifiées et méthodes de thérapie
EP3601528A4 (fr) Cellules et méthodes d'utilisation et de production de celles-ci
EP3528823A4 (fr) Déplacement latéral déterministe dans la préparation de cellules et de compositions à usages thérapeutiques
EP3407901A4 (fr) Expansion et différenciation des cellules de support de l'oreille interne, et méthodes d'utilisation de ces dernières
EP3568467A4 (fr) Lymphocytes t modifiés et leurs procédés d'utilisation
EP3273976A4 (fr) Cellules t modifiées, leurs procédés de préparation et utilisation
EP3364969A4 (fr) Méthodes de préparation de lymphocytes t pour traitement par lymphocytes t
EP3122181A4 (fr) Compositions et procédés pour expansion ex vivo des cellules souches hématopoïétiques humaines
DK3215611T3 (da) Peptid-medieret indgivelse af rna-guidet endonuklease i celler
EP3094720A4 (fr) Compositions et procédés de préparation de cellules respiratoires
GB201707048D0 (en) Expansion of gamma delta cells, compositions, and methods of use thereof
EP3134409A4 (fr) Composés et leur utilisation dans l'expansion de cellules souches hématopoïétiques et/ou cellules progénitrices hématopoïétiques
EP3359650A4 (fr) Activation et expansion de cellules t
EP3347449A4 (fr) Procédés d'expansion de cellules et compositions thérapeutiques
EP3420075A4 (fr) Production de cellules souches cancéreuses et leur utilisation
IL280240A (en) T-cells containing nef and methods for their production
NI201500177A (es) Formulación en perlas de cisteamina de liberación retardada
EP3518943A4 (fr) Méthodes de thérapie cellulaire adoptive
AU2018288863A1 (en) Methods for producing regulatory immune cells and uses thereof
EP2970885A4 (fr) Expansion de cellules souches adultes in vitro
EP3274079A4 (fr) Placenta artificiel et procédés de préparation
EP3645708A4 (fr) Compositions et méthodes de thérapies cellulaires adoptives contre le cancer
EP3273975A4 (fr) Noeud lymphatique artificiel in vitro de sensibilisation et de multiplication de lymphocytes t pour la thérapie et la cartographie des épitopes

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171025

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CZERNIECKI, BRIAN, J.

Inventor name: LOWENFELD, LEA

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180914

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0784 20100101ALI20180911BHEP

Ipc: A61K 39/00 20060101AFI20180911BHEP

Ipc: A61K 38/00 20060101ALI20180911BHEP

Ipc: C12N 5/0783 20100101ALI20180911BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190604

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210910